02 May 2003 : Original article
3-aminobenzamide, a poly(ADP-ribose)- polymerase inhibitor, reduces brain infarction and polymorphonuclear neutrophil infiltration after cerebral ischemia/reperfusion in mice
J. Couturier, N. Croci, M. Plotkine, I. MargaillMed Sci Monit 2003; 9(1): 16-0 :: ID: 15063
Abstract
Background:Poly(ADP-ribose) polymerase (PARP) was shown to be detrimental in cerebral ischemia but the mechanisms whereby PARP is deleterious have yet to be determined. They may include a role in polymorphonuclear neutrophil (PMN) infiltration known to aggravate ischemic damage. In this context, we investigated the effect of 3-aminobenzamide (3-AB), a PARP inhibitor, on brain damage and PMN infiltration in transient focal cerebral ischemia in mice.Material/Methods: Ischemia was induced in male Swiss mice, anaesthetized with chloral hydrate (400 mg/kg, i.p), by a 15 min-occlusion of the left middle cerebral artery using an intraluminal suture. Infarct volume was assessed 24 and 48 h after ischemia, and myeloperoxidase (MPO) activity used as an index of PMN infiltration at 48 h. Results:Treatment with 3-AB at 20, 40, 80 mg/kg, given i.p. 15 min before reperfusion, significantly reduced by 17–31% the infarct volume at 24 h. By contrast, 3-AB was devoid of neuroprotective activity at higher doses (160 and 320 mg/kg) or when treatment (40 mg/kg) was delayed by 2 h or 6 h after reperfusion. The neuroprotective effect of 3-AB (40 mg/kg, 15 min before reperfusion), was sustained up to 48 h after ischemia. With the same protocol, 3-AB also markedly reduced the PMN infiltration as evidenced by a 72%-decrease in MPO activity of damaged tissue at 48 h.Conclusions: Our results confirm that PARP activation contributes to brain damage. Moreover, for the first time, a quantitative study suggests that PARP is involved in PMN infiltration elicited by cerebral ischemia.
Keywords: poly(ADP-ribose) polymerase, cerebral ischemia, neutrophil, 3-aminobenzamide
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952